Search

Displaying results 5281 - 5290 of 7897 in total
  1. Drug

    Tozorakimab

    go.drugbank.com/drugs/DB16473
    Investigational

    history of exacerbations), and NCT06040086 (recruiting; symptomatic COPD with a history of exacerbations). … NCT04170543 (completed with results; diabetic kidney disease), NCT05624450 (recruiting; viral lung infection requiring supplemental oxygen), NCT05742802 (recruiting; long-term study in COPD patients with a

  2. Drug

    Ethyl pyruvate

    go.drugbank.com/drugs/DB05869
    Investigational

    CTI-01 (ethyl pyruvate) is a novel anti-inflammatory agent for the treatment of critical inflammatory conditions. … CTI-01 shows a potent anti-inflammatory and tissue protection activity in multiple animal models of disease including pancreatitis, ischemia-reperfusion injury, sepsis, renal injury and endotoxemia.

  3. Drug

    Neramexane

    go.drugbank.com/drugs/DB04926
    Investigational

    Neramexane is a low-to-moderate affinity uncompetitive NMDA receptor antagonist.

  4. Drug

    Elinzanetant

    go.drugbank.com/drugs/DB18968
    ApprovedInvestigational

    Elinzanetant is a non-hormonal, selective, dual neurokinin 1 (NK-1) and 3 (NK-3) receptor antagonist. … [L53798] By blocking receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons, which are hyperactivated due to estrogen decline in menopause, elinzanetant modulates neuronal activity involved

  5. Drug

    PI-166

    go.drugbank.com/drugs/DB05859
    Experimental

    PI-166 is a small organic compound with specific avidity to liver cancer cells.

  6. Drug

    GALE-301

    go.drugbank.com/drugs/DB17262
    Investigational

    GALE-301 is an investigational cancer immunotherapy. … It is made up of E39, an immunogenic peptide derived from the folate binding protein (FBP), and an immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF).[A254696,L44166,L44171]

  7. Drug

    PX-478

    go.drugbank.com/drugs/DB06082
    Investigational

    PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical trial in patients with advanced metastatic cancer and lymphoma.

  8. Drug

    Cilansetron

    go.drugbank.com/drugs/DB04885
    Experimental

    Cilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.

  9. Drug

    SYN-101

    go.drugbank.com/drugs/DB05958
    Experimental

    SYN101 is comprised of an immune cell specific antibody linked to an ALK5 inhibitor payload to selectively block TGF-b signalling in immune cells. … SYN-101 is an investigational antibody-drug conjugate developed for the treatment of cancer.

  10. Drug

    RPI-78M

    go.drugbank.com/drugs/DB05740
    Experimental

    RPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).